Drug Trial Radar · NCT04897516
Shorter Benznidazole Regimens Compared to the Standard Regimen for Chagas Disease
Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jul 28, 2021
Primary completion
Jun 1, 2026
Study completion Dec 1, 2026
Sponsor
- Lead sponsor
- Laboratorio Elea Phoenix S.A.Industry
- Sponsor type
- Industry
- Collaborators
- Drugs for Neglected Diseases
- First posted
- May 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chagas disease, a parasitic infection caused by Trypanosoma cruzi, is endemic in much of Latin America and affects people throughout the world. Currently treatment with the only two drugs effective against the infection, benznidazole and nifurtimox, has significant limitations including frequent adverse effects in adult patients. However, timely treatment is key to achieving global objectives of controlling the disease. The standard treatment has a long duration (60 days). NuestroBen will test the hypothesis that shorter treatment regimens of 14 days and 28 days will be non-inferior to the standard 60-day treatment while improving the safety profile.
Conditions
- Chagas Disease
Interventions
Short regimen of benznidazoleDrug
Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 2 weeks.
Short treatment with benznidazoleDrug
Benznidazole, under the brand name Abarax (100 mg tablet), 300 mg divided into three daily doses (100 mg every 08 hours) for 4 weeks.
Standard treatment with benznidazoleDrug
Benznidazole, 300 mg divided into three daily doses (100 mg every 08 hours), orally for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with sustained negativation of parasitemia according to the results of qualitative PCR testsTime frame: From the end of treatment, and up to 12 months of follow-up from the end of treatment.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben"
Buenos Aires, Argentina · Not yet recruiting
Fundación Huésped
Buenos Aires, Argentina · Recruiting
Hospital Francisco Javier Muñiz
Buenos Aires, Argentina · Recruiting
Hospital Donación Francisco Santojanni
Buenos Aires, Argentina · Not yet recruiting
Instituto de Cardiología de Corrientes "Juana Francisca Cabral"
Corrientes, Argentina · Recruiting
Centro de Chagas y Patología Regional, Hospital Independencia
Santiago del Estero, Argentina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.